SynthesisJournal of neurology, neurosurgery, and psychiatry2022
Disrupted reward processing in Parkinson's disease and its relationship with dopamine state and neuropsychiatric syndromes: a systematic review and meta-analysis.
Synthesis in Journal of neurology, neurosurgery, and psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Management of Anxiety in Parkinson's Disease.Movement disorders clinical practice · 2025Pooled it
- Differential Associations of Dopamine and Serotonin With Reward and Punishment Processes in Humans: A Systematic Review and Meta-Analysis.JAMA psychiatry · 2025Pooled it
- Research agenda to advance anhedonia assessment, understanding and treatment: an ECNP-GALENOS expert meeting report.BMJ mental health · 2026Review
- Depression in neurodegenerative disease: neurobiological mechanisms and emerging treatments.Molecular psychiatry · 2026Review
- Prevalence and state-dependent patterns of non-motor fluctuations in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Movement Disorder Patients with Depression Have Altered Corticostriatal Alpha-Beta Power Response to Reward and Loss.eNeuro · 2026Article
- Narrative Review of Body-First Versus Brain-First Prodromal Neuropsychiatric Symptoms in Parkinson's Disease.Cureus · 2026Review
- Functional bipartition of medial prefrontal cortex into salience detection and movement gain.bioRxiv : the preprint server for biology · 2026Article
- Potential Effects of Music on Non-Motor Symptoms in Parkinson's Disease: Translating Mechanisms to Therapy.Neurology international · 2026Review
- Impaired reward sensitivity in Parkinson's depression is unresponsive to dopamine treatment.Brain : a journal of neurology · 2025Article
- Decoding dynamic brain networks in Parkinson's disease with temporal attention.Scientific reports · 2025Article
- New developments in imaging in ALS.Journal of neurology · 2025Review
- Selective Effects of Substantia Nigra and Locus Coeruleus Degeneration on Cognition in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Corydaline Alleviates 1-Methyl-4-Phenylpyridium (MPPNeurochemical research · 2025Article
- Reward Decision Network Disconnection in Poststroke Apathy: A Prospective Multimodality Imaging Study.Human brain mapping · 2025Article
- The 7 Muses of Neuro-Creative Cycle: How some patients with Parkinson's disease can unleash latent creativity.AIMS neuroscience · 2025Article
- Exploring the Complex Relationship Between Antidepressants, Depression and Neurocognitive Disorders.Biomedicines · 2024Review
- Longitudinal decline in striatal dopamine transporter binding in Parkinson's disease: associations with apathy and anhedonia.Journal of neurology, neurosurgery, and psychiatry · 2023Article
- Resveratrol Promotes Autophagy to Improve neuronal Injury in Parkinson's Disease by Regulating SNHG1/miR-128-3p/SNCA Axis.Brain sciences · 2023Article
- Dimensions of apathy in Parkinson's disease.Brain and behavior · 2023Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
backgroundNeuropsychiatric symptoms are common in Parkinson's disease (PD) and predict poorer outcomes. Reward processing dysfunction is a candidate mechanism for the development of psychiatric symptoms including depression and impulse control disorders (ICDs). We aimed to determine whether reward processing is impaired in PD and its relationship with neuropsychiatric syndromes and dopamine replacement therapy.
methodsThe Ovid MEDLINE/PubMed, Embase and PsycInfo databases were searched for articles published up to 5 November 2020. Studies reporting reward processing task performance by patients with PD and healthy controls were included. Summary statistics comparing reward processing between groups were converted to standardised mean difference (SMD) scores and meta-analysed using a random effects model.
resultsWe identified 55 studies containing 2578 participants (1638 PD and 940 healthy controls). Studies assessing three subcomponent categories of reward processing tasks were included: option valuation (n=12), reinforcement learning (n=37) and reward response vigour (n=6). Across all studies, patients with PD on medication exhibited a small-to-medium impairment versus healthy controls (SMD=0.34; 95% CI 0.14 to 0.53), with greater impairments observed off dopaminergic medication in within-subjects designs (SMD=0.43, 95% CI 0.29 to 0.57). Within-subjects subcomponent analysis revealed impaired processing off medication on option valuation (SMD=0.57, 95% CI 0.39 to 0.75) and reward response vigour (SMD=0.36, 95% CI 0.13 to 0.59) tasks. However, the opposite applied for reinforcement learning, which relative to healthy controls was impaired on-medication (SMD=0.45, 95% CI 0.25 to 0.65) but not off-medication (SMD=0.28, 95% CI -0.03 to 0.59). ICD was the only neuropsychiatric syndrome with sufficient studies (n=13) for meta-analysis, but no significant impairment was identified compared tonon-ICD patients (SMD=-0.02, 95% CI -0.43 to 0.39).
conclusionReward processing disruption in PD differs according to subcomponent and dopamine medication state, and warrants further study as a potential treatment target and mechanism underlying associated neuropsychiatric syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.